Hedge Funds Are Betting On Regeneron Pharmaceuticals Inc (REGN)

Page 1 of 2

The market has been volatile as the Federal Reserve winds down its easy money policies. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 14 percentage points between June 25th and the end of October. SEC filings and hedge fund investor letters indicate that the smart money seems to be paring back their overall long exposure, and the funds’ movements is one of the reasons why the major indexes have retraced. In this article, we analyze what the smart money thinks of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and find out how it is affected by hedge funds’ moves.

Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a great stock to buy now? Investors who are in the know are taking an optimistic view. The number of long hedge fund positions rose by 3 in recent months. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article, we will examine companies such as The TJX Companies, Inc. (NYSE:TJX), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and General Motors Company (NYSE:GM) to gather more data points.

Follow Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

If you’d ask most stock holders, hedge funds are perceived as underperforming, outdated financial vehicles of years past. While there are more than 8000 funds in operation at the moment, Our researchers look at the masters of this club, about 700 funds. These money managers control most of all hedge funds’ total asset base, and by observing their highest performing investments, Insider Monkey has unearthed many investment strategies that have historically exceeded the S&P 500 index. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points annually for a decade in their back tests.

With all of this in mind, let’s take a look at the latest action regarding Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

What does the smart money think about Regeneron Pharmaceuticals Inc (NASDAQ:REGN)?

At the end of Q3, a total of 32 of the hedge funds tracked by Insider Monkey were bullish on this stock, an increase of 10% from the previous quarter. With hedgies’ sentiment swirling, there exists a select group of notable hedge fund managers who were boosting their holdings significantly (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Samuel Isaly’s OrbiMed Advisors has the largest position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN), worth close to $226.8 million, corresponding to 2.3% of its total 13F portfolio. Coming in second is Citadel Investment Group, managed by Ken Griffin, which holds a $131 million call position; 0.1% of its 13F portfolio is allocated to the company. Some other professional money managers that hold long positions contain Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management, John Overdeck and David Siegel’s Two Sigma Advisors, and D E Shaw.

Page 1 of 2